Home » Stocks » CYDY

CytoDyn, Inc. (CYDY)

Stock Price: $1.78 USD -0.07 (-3.53%)
Updated Jun 15, 2021 10:45 AM EDT - Market open
Market Cap 1.09B
Revenue (ttm) n/a
Net Income (ttm) -167.39M
Shares Out 612.88M
EPS (ttm) -0.29
PE Ratio n/a
Forward PE 10.81
Dividend n/a
Dividend Yield n/a
Trading Day June 15
Last Price $1.78
Previous Close $1.84
Change ($) -0.07
Change (%) -3.53%
Day's Open 1.82
Day's Range 1.76 - 1.83
Day's Volume 1,024,543
52-Week Range 1.63 - 10.01

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SAN FRANCISCO, June 10, 2021 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP is investigating potential derivative claims on behalf of shareholders of CytoDyn Inc. (OTC: CYDY) relating to possible false ...

6 days ago - PRNewsWire

Failure is not an option for this small-cap biotech developing a COVID-19 treatment.

Other stocks mentioned: GILD
1 week ago - The Motley Fool

CytoDyn Inc (OTCQB:CYDY) announced that the scientific journal Nature Communications published a study showing that leronlimab prevented nonhuman primates from being infected with Simian Human Immunodef...

1 week ago - Proactive Investors

Leronlimab to be studied as potential HIV PrEP drug in humans through an early clinical trial

1 week ago - GlobeNewsWire

Finding trending penny stocks in 2021 can be difficult; here's 4 to help you on your search The post Trending Penny Stocks to Buy Right Now? 4 For Your Watchlist appeared first on Penny Stocks to Buy, P...

Other stocks mentioned: AEI, DNN, VERB
1 week ago - PennyStocks

CytoDyn Inc (OTCQB:CYDY), which is developing Vyrologix (leronlimab-PRO 140) for multiple indications, revealed that Chiral Pharma Corporation placed its first purchase order for leronlimab under a comp...

2 weeks ago - Proactive Investors

VANCOUVER, Washington, June 01, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab), a CCR5 antagoni...

2 weeks ago - GlobeNewsWire

Chiral is simultaneously working on application for Emergency Use Authorization

2 weeks ago - GlobeNewsWire

12:27pm: Nasdaq joins the other indices in the green In the US, the Dow was up 148 points, 0.4%, to 34,471 at midday. The Nasdaq added 31 points, 0.2%, to 13,769, and the S&P 500 improved 14 points, 0.3...

Other stocks mentioned: AGCBF, AGNPF, AMC, AMYZF, CBDHF, FTSSF, IPNFF ...
2 weeks ago - Proactive Investors

Investors in a biotech startup developing a COVID-19 treatment claim the firm's leaders cashed out as stock prices surged during a publicity blitz for a drug that has yet to show any value as coronaviru...

2 weeks ago - GeekWire

CytoDyn Inc (OTCQB:CYDY), which is developing Vyrologix (leronlimab-PRO 140) for multiple indications, has said that its Brazilian distribution partner Biomm SA (BVMF:BIOM3) plans to submit an authoriza...

2 weeks ago - Proactive Investors

VANCOUVER, Washington, May 27, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 a...

2 weeks ago - GlobeNewsWire

CytoDyn Inc (OTCQB:CYDY) has found its new CFO in-house, promoting Vice President, Corporate Controller, Antonio Migliarese, the company announced.  Migliarese joined CytoDyn in January 2020, and he has...

3 weeks ago - Proactive Investors

VANCOUVER, Washington, May 20, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 a...

3 weeks ago - GlobeNewsWire

After facing rebuke from FDA, CytoDyn Inc (OTC: CYDY) plans to submit the topline results of its CD12 Phase 3 trial of Vyrologix (leronlimab-PRO 140) for severe to critically ill COVID-19 patients to re...

4 weeks ago - Benzinga

CytoDyn Inc (OTCQB:CYDY) plans to submit the topline results of its CD12 Phase 3 clinical trial of Vyrologix (leronlimab-PRO 140) for severe to critically ill COVID-19 patients to regulatory agencies, i...

4 weeks ago - Proactive Investors

The FDA has accused CytoDyn Inc (OTC: CYDY) of trying to pick and choose data from two failed studies of leronlimab in COVID-19 patients to claim the drug is effective. In March, the Phase 3 trial of Cy...

4 weeks ago - Benzinga

Finalized data analysis shows CD12 trial reached almost all of its major secondary  endpoints in a subpopulation (62 patients) of critically ill COVID-19

4 weeks ago - GlobeNewsWire

VANCOUVER, Washington, May 17, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 a...

4 weeks ago - GlobeNewsWire

Los Angeles, California--(Newsfile Corp. - May 17, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against CytoDyn Inc. ("CytoDyn"...

4 weeks ago - Newsfile Corp

New York, New York--(Newsfile Corp. - May 17, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of CytoDyn Inc. (OTCQB: CYDY) between March 27, 2020 an...

4 weeks ago - Newsfile Corp

New York, New York--(Newsfile Corp. - May 16, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of CytoD...

1 month ago - Newsfile Corp

New York, New York--(Newsfile Corp. - May 15, 2021) - WHY:Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of CytoDyn Inc. (OTCQB: CYDY) between March 27, 2020 and...

1 month ago - Newsfile Corp

New York, New York--(Newsfile Corp. - May 14, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of CytoDyn Inc. (OTCQB: CYDY) alleging that the ...

1 month ago - Newsfile Corp

New York, New York--(Newsfile Corp. - May 14, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of CytoDyn Inc. (OTCQB: CYDY) between March 27, 2020 an...

1 month ago - Newsfile Corp

New York, New York--(Newsfile Corp. - May 14, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased CytoDyn Inc. ("CytoDy...

1 month ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - May 14, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against CytoDyn Inc. ("CytoDyn"...

1 month ago - Newsfile Corp

New Orleans, Louisiana--(Newsfile Corp. - May 13, 2021) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have unti...

1 month ago - Newsfile Corp

LOS ANGELES--(BUSINESS WIRE)---- $CYDY #investors--The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against CytoDyn, Inc. (CYDY)

1 month ago - Business Wire

Los Angeles, California--(Newsfile Corp. - May 13, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against CytoDyn Inc. ("CytoDyn"...

1 month ago - Newsfile Corp

CytoDyn Inc (OTCQB:CYDY), a late-stage biotechnology company developing leronlimab (Vyrologix or PRO 140) for multiple therapeutic indications, has executed an exclusive supply and distribution agreemen...

1 month ago - Proactive Investors

Macleods is one of the largest pharmaceutical companies in India with presence in over 140 countries

1 month ago - GlobeNewsWire

NEW YORK, May 13, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CytoDyn Inc. ("CytoDyn" or the "Company") (OTCMKTS: CYDY). Such investors are advised to contact Ro...

1 month ago - PRNewsWire

New York, New York--(Newsfile Corp. - May 12, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of CytoDyn Inc. (OTCQB: CYDY) between March 27, 2020 an...

1 month ago - Newsfile Corp

RADNOR, Pa.--(BUSINESS WIRE)---- $CYDY #classaction--Deadline in 5 Days: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Class Action Lawsuit Against CytoDyn Inc. (CYDY)

1 month ago - Business Wire

Los Angeles, California--(Newsfile Corp. - May 12, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against CytoDyn Inc. ("CytoDyn"...

1 month ago - Newsfile Corp

Radnor, Pennsylvania--(Newsfile Corp. - May 11, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States Dist...

1 month ago - Newsfile Corp

Radnor, Pennsylvania--(Newsfile Corp. - May 10, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors of CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn") that a securities fraud class actio...

1 month ago - Newsfile Corp

Radnor, Pennsylvania--(Newsfile Corp. - May 7, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors of CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn") that a securities fraud class action...

1 month ago - Newsfile Corp

Drs. Pourhassan, Recknor, Seethamraju and Nicolas will appear in a one-hour segment beginning at 5:00 pm PT / 8:00 pm ET, Sunday, May 9

1 month ago - GlobeNewsWire

New Orleans, Louisiana--(Newsfile Corp. - May 6, 2021) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until...

1 month ago - Newsfile Corp

NEW YORK, May 5, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of CytoDyn Inc. (OTC: CYDY) between March 27, 2020 and March 9, 2021, i...

1 month ago - PRNewsWire

CytoDyn Inc (OTCQB:CYDY) announced that it has struck an agreement to partner with the Academic Research Organization (ARO) - Albert Einstein Israelite Hospital (AEIH), in São Paulo, Brazil to run two t...

1 month ago - Proactive Investors

Interim analysis for critically ill population will be conducted when enrollment reaches about 120 patients or 40% of the approximate 300 patients

1 month ago - GlobeNewsWire

New York, New York--(Newsfile Corp. - May 4, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of CytoDyn Inc. (OTCQB: CYDY) alleging that the C...

1 month ago - Newsfile Corp

Radnor, Pennsylvania--(Newsfile Corp. - May 4, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States Distr...

1 month ago - Newsfile Corp

New York, New York--(Newsfile Corp. - May 4, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of CytoDy...

1 month ago - Newsfile Corp

RADNOR, Pa., May 3, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that securities fraud class action lawsuit has been filed against CytoDyn Inc. (OTCMKTS: CYD...

1 month ago - PRNewsWire

VANCOUVER, Washington, May 03, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 a...

1 month ago - GlobeNewsWire

VANCOUVER, Washington, May 03, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (Vyrologix or PRO 140), a CCR5...

1 month ago - GlobeNewsWire

About CYDY

CytoDyn Inc. operates as a late-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. Its Leronlimab is in a class of therapeutic monoclonal antibodies designed to address unmet medical needs in the areas of human immunodeficiency virus (HIV), cancer, immunology, and novel coronavirus disease (COVID-19). It has completed a Phase 3 pivotal trial with leronlimab in combination with antiretroviral therapi... [Read more...]

Industry
Biotechnology
Stock Exchange
OTCMKTS
Ticker Symbol
CYDY
Full Company Profile

Financial Performance

Financial Statements